Fig. 6

The effect of SOX2OT on BCSC growth and tumourigenicity in vivo. a Tumours collected from mice are shown. b Tumour weights of the sh-SOX2OT and sh-NC treatment groups were measured and analysed. c Tumour volume curves of the sh-SOX2OT and sh-NC treatment groups were measured and analysed. d The tumour-free proportions of the sh-SOX2OT and sh-NC treatment groups were measured and analysed. Knockdown of SOX2OT inhibited bladder cancer cell growth in vivo. e and f Knockdown of SOX2OT increased miR-200c expression, decreased SOX2 and SOX2 target gens expression, and inhibited EMT in BCCs in vivo. g: Knockdown of SOX2OT decreased SOX2 expression, and SOX2OT and SOX2 were colocalized in BCCs in vivo. h and i Knockdown of SOX2OT decreased SOX2 and ki67 expression in BCCs in vivo. j Schematic diagram of the cell fluorescence trace system. k and l Knockdown of SOX2OT significantly decreased the proportion of sh-SOX2OT cells in xenografts. The data are shown as the mean ± SD. *p < 0.05; **p < 0.01